New hope for advanced skin cancer patients: immunotherapy trial seeks better First-Line option
NCT ID NCT06981325
Summary
This study is testing whether the immunotherapy drug cemiplimab works as a first treatment for advanced basal cell carcinoma, a type of skin cancer that can't be removed with surgery or radiation. The trial will enroll 34 adults with this advanced cancer who haven't tried other targeted medications. Researchers will give cemiplimab every 3 weeks for up to a year and track how well tumors shrink and how long the treatment keeps the cancer under control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA (BCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Helios Klinikum Erfurt
RECRUITINGErfurt, Germany
-
Helios Klinikum Oberhausen
RECRUITINGOberhausen, Germany
-
Johannes Wesling Klinikum
RECRUITINGMinden, Germany
-
Nationales Centrum für Tumorerkrankungen (NCT)
RECRUITINGHeidelberg, Germany
-
Universitätsklinikum Erlangen
RECRUITINGErlangen, Germany
-
Universitätsklinikum Leipzig
RECRUITINGLeipzig, Germany
-
Universitätsklinikum Tübingen
RECRUITINGTübingen, Germany
Conditions
Explore the condition pages connected to this study.